(R)-5-((4-chlorophenyl)sulfonyl)-8-fluoro-4-methyl-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline | 959997-02-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-5-((4-chlorophenyl)sulfonyl)-8-fluoro-4-methyl-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline
• 英文别名: (4R)-5-(4-chlorophenyl)sulfonyl-8-fluoro-4-methyl-1,4-dihydropyrazolo[4,3-c]quinoline
• CAS: 959997-02-5
• 化学式: C₁₇H₁₃ClFN₃O₂S
• 分子量: 377.827
• InChiKey: OTXHDBQTORDBPA-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  74.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl 3-[N-(4-fluorophenyl)(4-chlorophenyl)sulfonamino]butanoate 在 aluminum (III) chloride 、 草酰氯 、 一水合肼 、 溶剂黄146 、 三氟乙酸 作用下， 以 乙醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 13.25h， 生成 (R)-5-((4-chlorophenyl)sulfonyl)-8-fluoro-4-methyl-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline 、 (S)-5-((4-chlorophenyl)sulfonyl)-8-fluoro-4-methyl-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline
  参考文献：
  名称：

  Discovery of (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch

  摘要：

  Herein, we describe our strategy to design metabolically stable gamma-secretase inhibitors which are selective for inhibition of A beta generation over Notch. We highlight our synthetic strategy to incorporate diversity and chirality. Compounds 30 (ELND006) and 34 (ELND007) both entered human clinical trials. The in vitro and in vivo characteristics for these two compounds are described. A comparison of inhibition of A beta generation in vivo between 30, 34, Semagacestat 41, Begacestat 42, and Avagacestat 43 in mice is made. 30 lowered A in the CSF of healthy human volunteers.

  DOI：

  10.1021/jm301741t

文献信息

• Discovery of (<i>R</i>)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND006) and (<i>R</i>)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch
  作者：Gary Probst、Danielle L. Aubele、Simeon Bowers、Darren Dressen、Albert W. Garofalo、Roy K. Hom、Andrei W. Konradi、Jennifer L. Marugg、Matthew N. Mattson、Martin L. Neitzel、Chris M. Semko、Hing L. Sham、Jenifer Smith、Minghua Sun、Anh P. Truong、Xiaocong M. Ye、Ying-zi Xu、Michael S. Dappen、Jacek J. Jagodzinski、Pamela S. Keim、Brian Peterson、Lee H. Latimer、David Quincy、Jing Wu、Erich Goldbach、Daniel K. Ness、Kevin P. Quinn、John-Michael Sauer、Karina Wong、Hongbin Zhang、Wes Zmolek、Elizabeth F. Brigham、Dora Kholodenko、Kang Hu、Grace T. Kwong、Michael Lee、Anna Liao、Ruth N. Motter、Patricia Sacayon、Pamela Santiago、Christopher Willits、Frédérique Bard、Michael P. Bova、Susanna S. Hemphill、Lam Nguyen、Lany Ruslim、Kevin Tanaka、Pearl Tanaka、William Wallace、Ted A. Yednock、Guriqbal S. Basi

  DOI：10.1021/jm301741t

  日期：2013.7.11

  Herein, we describe our strategy to design metabolically stable gamma-secretase inhibitors which are selective for inhibition of A beta generation over Notch. We highlight our synthetic strategy to incorporate diversity and chirality. Compounds 30 (ELND006) and 34 (ELND007) both entered human clinical trials. The in vitro and in vivo characteristics for these two compounds are described. A comparison of inhibition of A beta generation in vivo between 30, 34, Semagacestat 41, Begacestat 42, and Avagacestat 43 in mice is made. 30 lowered A in the CSF of healthy human volunteers.